U.K. Cancer Drug Fund May Shift To ‘Coverage With Evidence Development’-Style Approach

Fund would revaluate benefits – and pricing – of drugs it covers, adding extra layer of complexity to accessing new medicines for Britain’s cancer patients.

With the U.K.’s Cancer Drugs Fund (CDF) being rapidly emptied by the inclusion of new drugs with ever higher prices it was probably only a matter of time before the British government and the publicly-funded National Health Service would propose a role for the CDF in re-evaluating drugs and negotiating prices with industry.

The NHS in England and its Clinical Reference Group for Chemotherapy (CFG-C) are proposing that the CFG-C’s panel of expert...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United Kingdom

More from Europe